Study markers that predict how sarcoidosis changes over time
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing clinical trials.
This study follows adults with sarcoidosis to see which body “risk signals” (biomarkers) can predict whether the disease will get better or worse. It may help doctors monitor sarcoidosis more closely and choose the right treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older) with a confirmed diagnosis of sarcoidosis
- Your sarcoidosis diagnosis followed accepted standards, usually including a tissue biopsy and ruling out other causes
- You can safely take part in the study procedures (you must be able to tolerate them)
- You are not pregnant and not breastfeeding
- You do not have other conditions that could change the study test results, like HIV, common variable immune problems, or autoimmune disease
- You do not have other lung scarring diseases at the same time, like hypersensitivity pneumonitis or idiopathic pulmonary fibrosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a steroid combination medicine called Compound Betamethasone works well for people recently diagnosed with pulmonary sarcoidosis who haven't yet had treatment. The goal is to see if it can control the disease with fewer side effects than usual steroids.
This study looks at how the immune system works in people with sarcoidosis. It may help researchers find better ways to diagnose or treat the disease in the future.
This study follows people with sarcoidosis that may or may not be affecting the heart. It uses special scans (PET and MRI) to look for heart involvement and track how the disease changes over time.
This study checks whether a special heart scan called PET/MRI can predict how sarcoidosis may affect your heart. It may help doctors better estimate heart risk and plan follow-up based on scan findings.
This study collects and analyzes tissue or blood samples to better understand heart sarcoidosis and related inflammatory heart conditions. It may help doctors confirm diagnoses and improve care, especially in people with rhythm problems or results on heart scans.
This trial tests a new medicine, XTMAB-16, for people with pulmonary sarcoidosis (lung inflammation) that may also affect other parts of the body. The study first checks how the body handles different doses, then looks for signs of improvement.
Hear when a new Sarcoidosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.